For the generation that reached sexual maturity in the 1960s, the pill became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought this will change everything and it clearly haschanging practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.

Includes supplementary material: sn.pub/extras

Klappentext

For the generation that reached sexual maturity in the 1960s, the "pill" became synonymous with sexual freedom and started a sexual revolution. For women it meant freedom from the fear of pregnancy, and for men enhanced sexual opportunity. The new era of the pill has nothing to do with fertility, but everything to do with sex. The first orally effective prescr- tion drug for treating erectile dysfunction (ED) was marketed in 1998. ® Sildenafil (Viagra ) has rejuvenated the aging male veterans of the sexual revolution, forever changed the science of sexual medicine, and tra- formed society's perspective on aging and sex. This class of drugs, known as oral phosphodiesterase inhibitors (PDE-type 5), is highly effective in the treatment of ED. Since its introduction there has been a much greater awa- ness of ED, its comorbidities, and its effects on the quality of life. In 1997, while preparing to address the Endocrine Society on the occasion of the 92nd American Urological Association meeting, I first looked at the p- clinical studies of sildenafil. I thought "this will change everything" and it clearly has-changing practice patterns in sexual medicine, and the at- tudes of patients, potential patients, and their partners. Two new PDE-type ® ® 5 inhibitors, tadalafil (Cialis ) and vardenafil (Levitra ), were first approved by the European Committee for Proprietary Medicinal Products and subsequently by the Food and Drug Administration in 2003 and 2004.

Inhalt
Physiology and Pharmacology of Erectile Dysfunction.- Epidemiology of Erectile Dysfunction.- Pharmacology of Phosphodiesterase Inhibitors.- Sildenafil Citrate, the Classic PDE5 Inhibitor.- Tadalafil.- Vardenafil Clinical Trials Experience.- Erectile Dysfunction Assessment and Management in Primary Care Practice.- When to Refer the Patient With Erectile Dysfunction to a Specialist.- Erectile Dysfunction.- Is Diabetic Erectile Dysfunction More Difficult to Treat?.- Depression and Antidepressant-Associated Erectile Dysfunction.- Intracavernous, Transurethral, and Topical Therapies for Erectile Dysfunction in the Era of Oral Pharmacotherapy.- Androgen Deficiency in the Aging Male.- Central Activation of Erection and Clinical Experience.- Sustaining the Cure.- Prevention and Treatment of Erectile Dysfunction Utilizing Lifestyle Changes and Dietary Supplements.- Pharmacological Strategies in the Management of Rapid Ejaculation.- Sexual Dysfunction After Radical Prostatectomy and the Use of PDE-5 Inhibitors.- Female Sexual Dysfunction.